Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction
Xin Zhao(NYU Langone Health), Scott M. Lippman(UC San Diego Health System), Raymond J. Lim(University of California, Los Angeles), Kaloyan M. Tsanov(Memorial Sloan Kettering Cancer Center), Francisco M. Barriga(Memorial Sloan Kettering Cancer Center), Yu-Jui Ho(Memorial Sloan Kettering Cancer Center), Teresa Davoli(NYU Langone Health), William N. William(The University of Texas MD Anderson Cancer Center), Bin Liu(Guangzhou University of Chinese Medicine), Steven M. Dubinett(University of California, Los Angeles), Yushen Du(University of California, Los Angeles), Maria Trifas(NYU Langone Health), Scott W. Lowe(Memorial Sloan Kettering Cancer Center)
Cited by 12
Related Papers
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|The Lancet Oncology|2016|1.1k
Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity
|Genes & Development|2011|990
Dissecting eIF4E action in tumorigenesis
|Genes & Development|2007|476